Jose Costa MD, FACP

Professor of Pathology and of Medicine (Medical Oncology); Director, Translational Diagnostics; Director, Musculoskeletal Tumor Program

Research Interests

Oncology; Carcinogenesis; Tumor development and progression; Advanced diagnostics; Molecular diagnostics; Diagnosed genetic alterations in tumors; Cancer risk detection by mutational load distribution analysis


Research Summary

The laboratory studies the natural history of tumors. We look at the process of tumor development and tumor progression at the systems level in an attempt to understand the role played by somatic cell genetics, gene function, environment, and chance. Results obtained during the last decade indicate that during the pre-tumoral stage diversity among somatic cells is maintained by mutation and drift and that certain clones expand under the strength of selection and the influence of disturbance. Although the majority of clones harboring mutations disappear, diversity is constantly generated by background levels of spontaneous mutation. In contrast, in overt tumors that often exhibit a “mutator phenotype,” diversity is maintained by rules that are reminiscent of the ecological principles that govern diversity in macroscopic systems. Insights into the dynamics of tumor formation and tumor progression suggest new ways to utilize known therapeutic strategies and may afford novel ways to measure cancer risk.


Selected Publications

  • Costa, J., Gonzalez-Garcia, I., and Sole, R. (2006). Spatial Dynamics in Cancer, in Complex Systems Science in Biomedicine (Deisboeck, T.S., and Kresh, J.Y.), Chapter 6.2, pp. 557-572.
  • Lage, J.M., et al. (2003). Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res. 13:294-307.
  • Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. (1998) Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. Journal of Clinical Pathology, Vol 16(3): 1158-1166.
  • Dillon DA, Howe CL, Bosari S, Costa J. (1998) The molecular biology of breast cancer: Accelerating clinical applications. Critical Reviews in Oncogenesis. 9(2): 125-140.
  • Bautista D, Obrador A, Moreno V, Cabeza E, Canet R, Benito E, Bosch X, Costa JC. (1997) Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. Cancer Epidemiology, Biomarkers, and Prevention 6: 57-61.
  • Pinto MM, Emanuel JR, Chaturvedi V, Costa JC. (1997) Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytologica, 41 (2): 427-434.
  • Fazeli A, Steen RG, Dickinson SL, Bautista D, Dietrich WF, Bronson RT, Bresalier RS, Lander Es, Costa JC, Weinberg RA. (1997) p53, apoptosis and colon cancer, PNAS.
  • Guillou L, Coindre J.M, Bonichon F, Biu NB, Terrier P, Collin F, Vilain M.O, Mandard A.M, ld Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre X, Costa J.C. (1997) A comparative study of the NCI and FNCLLL grading systems in a population of 410 adult patients with a soft tissue sarcoma. J Clinical Oncology 15: 350-362.

Edit Profile